Navigation Links
Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon
Date:11/11/2009

NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB; Frankfort Borse: PBO) has announced that early experimental results have indicated that its PulmoBind(TM) product candidate can be potentially used for the early detection and follow-up of many conditions that affect the physical and/or biological integrity of the Pulmonary Circulation. These early results, if confirmed by further experiments, would broaden the range of conditions that PulmoBind(TM) is able to diagnose.

"We are very pleased with these early results. To date, we have mainly concentrated on the use of PulmoBind(TM) as a diagnostic agent for Pulmonary Hypertension (PH) and Pulmonary Embolism (PE). While our work in these areas continues, early experimental results have indicated that PulmoBind(TM) could be used to diagnose a wide range of Pulmonary Vascular diseases associated with lung disorders, heart disease and connective tissue disease. For example, lung disorders associated with HIV, Cirrhosis and Shistosomiasis are all conditions that we believe could potentially be diagnosed using PulmoBind(TM). If our experimental results can be confirmed, then PulmoBind(TM) has great potential as a front-line test to either confirm or exclude disorders of the Pulmonary Circulation in patients who present with "shortness of breath". PulmoBind(TM) could also help in predicting outcomes in these patients and guiding their therapy." - Garry McCann, CEO Pulmo BioTech Inc.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to b
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
2. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
3. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
4. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
7. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
10. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
11. Pulmo BioTech Inc. Completes Bio-Distribution Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
(Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
(Date:9/17/2014)... , Sept. 17, 2014  Rebiotix Inc. announced this morning ... lead product candidate, RBX2660 (microbiota suspension) will be presented in ... conference in Philadelphia from October 8-12. ... during the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 2American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 3American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 4American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 5American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 6American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 7Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 2Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 3Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 4
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Social networking ... new study. For people who are obese, sites ... convenient source of support from doctors as well as ... media over other methods is that it offers the ... for day-to-day use when compared to traditional approaches," the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Sept. 17, 2014 (HealthDay News) -- Positive messages about ... people kick the habit, a new study suggests. ... better to "loss-framed" messages about the harmful effects of ... whenever they want benefit more from "gain-framed," or positive, ... The researchers concluded that using a mix of both ...
(Date:9/17/2014)... 2014 Many countries choose to kill ... immunizations. The total number of poultry exceeds 10 billion ... will result in huge losses. Therefore, it is quite ... , Avian influenza vaccines have been used for more ... China began to use H5N1 avian influenza vaccines voluntarily ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
Breaking Medicine News(10 mins):Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
... Campath, CAMBRIDGE, Mass. and WAYNE, N.J., Sept. ... Bayer HealthCare Pharmaceuticals Inc.,(NYSE: BAY ) today ... has approved a supplemental biologics license application (sBLA) ... for the treatment of B-cell chronic lymphocytic leukemia ...
... LLC, today announced the,U.S. Food and Drug Administration ... use in intervertebral fusion procedures.,Included are versions to ... without the need for supplemental fixation. Fusion ... performed by,neurosurgeons and orthopedic spine surgeons. The InterPlate ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... chronic,lymphocytic leukemia (CLL). CLL is a slowly progressing ... new cases diagnosed every year in,the United States, ...
... new implant for marketing, NEW YORK, Sept. 21 ... products, technology and education for the,small bone and joint ... Spacer has been cleared by the FDA for marketing ... of surgically implanted, degradable,spacers to four applications with two ...
... you eat the right grains for breakfast, such as ... sugar is facilitated after breakfast, lunch, and dinner. It ... this effect all day. This is due to a ... of indigestible carbohydrates that occur in certain grain products. ...
... Aviv Universitys Sackler School of Medicine is, quite simply, a ... of a small number of surgeons in the world who ... has developed a novel laser device that promises to revolutionize ... now, is expected to give most practicing eye surgeons the ...
Cached Medicine News:Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 2Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 3Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 5Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:Glaucoma surgery in the blink of an eye 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: